Data presented at the American Urological Association in New Orleans show a 50% drop in PSA testing in the years since the USPSTF issued its controversial D recommendation. Some see a "chilling" effect, but not all see a problem.
To Vanderbilt University’s Sam Chang, MD, the drop-off in prostate cancer screening since 2012 represents a “chilling effect.” To Otis Brawley, MD, chief medical officer for the American Cancer Society, the change represents more conscientious conversations between doctors and patients.
But whatever one’s point of view, the data represented Monday at the American Urological Association annual meeting in New Orleans certainly grabbed headlines: According to a study presented by Ryan Werntz, MD, the controversial 2012 guideline change from the US Preventive Task Force (USPSTF) has triggered a profound shift in clinical practice.
Werntz, a urologic resident at Oregon Health & Science University (OHSU), found that the overall rate of prostate-specific antigen (PSA) testing had dropped 50% among primary care physicians at OHSU since the guideline change.
According to a report from the meeting by Oncology Live, the decline was most significant among men aged 50 to 70 years—a group highly likely to benefit from testing.
Werntz and others echoed concerns that were heard immediately in May 2012, when the USPSTF stunned urologists and the cancer prevention community by giving the PSA test a D rating, saying the harms outweighed the benefits. “If you look back before PSA was a big part of prostate cancer screening, 20% to 25% of men would often first see a physician with back pain and be subsequently diagnosed with metastatic disease,” he told Oncology Live.
USPSTF’s 2012 change was rooted in the belief, shared by some in managed care, that widespread PSA testing was causing too many men to be biopsied and overtreated for slow-growing cancers that posed no immediate risk. This caused unnecessary complications like incontinence and impotence. But supporters of PSA testing say it has saved lives.
In March 2014, Peter R. Carroll, MD, MPH, of the University of California at San Francisco, presented updated prostate cancer screening guidelines at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in direct response to USPSTF, and said, “We achieved a 45% reduction in mortality in prostate cancer in the United States, in contrast with an increase worldwide. Yet, the USPSTF gives it a D.”
NCCN recommended a middle ground for PSA testing in which screening would be less frequent than and guided by risk factors. Indications for biopsies would be driven by “highly suspicious” digital rectal exams that followed an elevated PSA result.
The American Cancer Society says on its web site that the USPSTF guideline differs from its own recommendation, which calls for individual decisions based on understanding of risks. Brawley, who at the time of the 2012 recommendation was skeptical how much screening would decline, told HealthDay this week that he sees a trend away from “thoughtless” to more focused screening, “with informed decision-making going on between doctor and patient.”
Werntz’ figures from OHSU showed that PSA testing in new patients age 40 or older declined from 14% in the years prior to the recommendation to 7% in the years that followed.
Reference
Werntz R, Martinez-Acevedo AC, Conlin MJ, et al. Trends in PSA utilization by primary care physicians: impact of the USPSTF recommendation. Presented at the American Urological Association Annual Meeting; New Orleans, Louisiana, May 18, 2015. Abstract PD44-02.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More